Literature DB >> 26460078

[Corrigendum] Activation of sonic hedgehog signaling enhances cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma.

Liang Chang1, Dan Zhao2, Hui-Bin Liu2, Qiu-Shi Wang2, Ping Zhang1, Chen-Long Li1, Wen-Zhong Du1, Hong-Jun Wang1, Xing Liu1, Zhi-Ren Zhang2, Chuan-Lu Jiang1.   

Abstract

Mol Med Rep 12: [Related article:] 6702–6710, 2015; DOI: 10.3892/mmr.2015.4229 After the publication of the article, it has been brought to the authors' attention by an interested reader that we had made an error regarding the presentation of certain data in the manuscript. The error relates to the presentation of Figs. 1 and 2 in the paper: The control panels for Fig. 1C [labelled 'cyclopamine (µM)'] and Figs. 2B and C [labelled 'rhSSH (µg/ml)'] were derived from the same image. The control U251 cells, featured in Fig. 1 and Figs. 2B and C, were treated without cyclopamine and rhSHH. Therefore, the U251 cells treated without cyclopamine and rhSHH were considered as a control group compared with U251 cells that were separately treated with cyclopamine or rhSHH, and these were photographed randomly. A new Fig. 2 is provided, which contains the correct data for the control panels for Figs. 2B and C.

Entities:  

Year:  2015        PMID: 26460078      PMCID: PMC4758290          DOI: 10.3892/mmr.2015.4414

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


Mol Med Rep 12: 6702–6710, 2015; DOI: 10.3892/mmr.2015.4229 After the publication of the article, it has been brought to the authors' attention by an interested reader that we had made an error regarding the presentation of certain data in the manuscript. The error relates to the presentation of Figs. 1 and 2 in the paper: The control panels for Fig. 1C [labelled 'cyclopamine (µM)'] and Figs. 2B and C [labelled 'rhSSH (µg/ml)'] were derived from the same image. The control U251 cells, featured in Fig. 1 and Figs. 2B and C, were treated without cyclopamine and rhSHH. Therefore, the U251 cells treated without cyclopamine and rhSHH were considered as a control group compared with U251 cells that were separately treated with cyclopamine or rhSHH, and these were photographed randomly. A new Fig. 2 is provided, which contains the correct data for the control panels for Figs. 2B and C.
Figure 2

rhSHH enhances the adhesion, invasion and migration of U251 cells. (A) U251 cells were incubated for 24 h with various concentrations of rhSHH. Cells were seeded into 96-well plates coated with fibronectin. After 1 h, the adhered cells were analyzed by MTT assay. The adhesion rate was expressed as a percentage of the control (0 µg/ml). (B) U251 cells were seeded in the upper wells without matrigel coating and treated with various concentrations of rhSHH. After 12 h, cells on the bottom side of the filter were fixed, stained and counted (magnification, ×400). The migration rate was expressed as a percentage of the control (0 µg/ml). (C) U251 cells were seeded in the upper wells with matrigel coating and treated with various concentrations of rhSHH. After 24 h, cells on the bottom side of the filter were fixed, stained and counted (magnification, x400). The invasion rate was expressed as a percentage of the control (0 µg/ml). Values are expressed as the mean ± standard deviation of three independent experiments. *P<0.001, compared with controls. rhSHH, recombinant human sonic hedgehog N-terminal peptide.

The selection of the same image for the control panels in Figs. 1 and 2 do not affect the overall conclusions in the paper. We would like to thank the reader who pointed out this error, and to apologize for any inconvenience caused.
  1 in total

1.  Hedgehog Suppresses Paclitaxel Sensitivity by Regulating Akt-Mediated Phosphorylation of Bax in EGFR Wild-Type Non-Small Cell Lung Cancer Cells.

Authors:  Yun-Chieh Tu; Wei-Chen Yeh; Hsin-Hsien Yu; Yu-Cheng Lee; Bor-Chyuan Su
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.